The U.S. Supreme Court decided today that claims to isolated genomic DNA are not patentable subject matter and thus invalid. This decision rendered invalid patent claims owned by Myriad Genetics as well as thousands of patent claims of others to such molecules. However, Myriad’s claims to complementary DNA (cDNA) molecules were held to be valid.

In the decision, authored by Justice Thomas, the Court held that claims to isolated genomic DNA molecules fell squarely within the law of nature exception to patentable subject matter. According to the Court, Myriad found the location of the BRCA1 and BRCA2 genes, but that discovery, by itself, did not render the BRCA genes a “new...composition[s] of matter” under §101. The Court was not moved by Myriad’s argument that they undertook extensive effort to locate the gene sequences associated with an increased risk of breast cancer. The Court also rejected the argument that isolating DNA from the human genome severed chemical bonds and thereby created a non-naturally occurring molecule, pointing out that Myriad’s claims did not rely on the chemical changes that result from isolation. Instead, the claims focus on the genetic information encoded in the BRCA1 and BRCA2 genes. The Court also rejected the argument that the U.S. Patent and Trademark’s past practice of awarding gene patents was entitled to deference, pointing out that the U.S. government now argued to the Court that isolated genomic DNA was not patent eligible.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sterne, Kessler, Goldstein & Fox P.L.L.C. | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.